SynAct Pharma AB (publ) (“SynAct”) today publishes the interim report for the first quarter 2026.
“As we close the first quarter of 2026, SynAct Pharma is in a stronger position than at any previous point in the company’s history: clinically, operationally and financially. The defining moment of this year is close.”
Jeppe Øvlesen,
Chief Executive Officer
First quarter 2026 (January – March)
- The Group’s net sales amounted to SEK 0 (0) thousand
- Operating expenses amounted to SEK 30,558 (28,098) thousand, an increase of 9%
- The Group’s loss after tax amounted to SEK 25,487 (24,684) thousand
- The Group’s earnings per share before and after dilution amounted to -0.48 (-0.51) SEK
- Cash flow from operating activities amounted to SEK -32,952 (-28,826) thousand
- Cash flow from financing activities amounted to SEK 45,308 (19,703) thousand
- Cash flow for the period amounted to SEK 12,356 (-9,123) thousand
- Cash and cash equivalents at the end of the period amounted to SEK 65,782 (51,161) thousand
Significant events during the first quarter
- Jan 9 – The Board of Directors of SynAct Pharma AB (publ) has resolved on the repurchase of own shares
- Jan 30 – SynAct Pharma initiates Phase 2 study in respiratory insufficiency
- Feb 6 – SynAct Pharma successfully reached recruitment goal in Ph2b ADVANCE study
- Feb 24 – SynAct Pharma appoints Ann Kristin Led as Chief Financial Officer
- Mar 2 – SynAct Pharma has carried out a directed issue of new shares of approximately 51.9 MSEK
- Mar 26 – SynAct Pharma doses first patients in the Phase 2 RESOVIR-2 study with resomelagon
- Mar 31 – Change in number of shares and voting rights in Synact Pharma AB
Significant events after the end of the period
- Apr 23 – SynAct Pharma’s Nomination Committee ahead of the 2026 Annual General Meeting
- May 6 – SynAct Pharma completes dosing for last patient in Phase 2b ADVANCE study
- May 7 –Notice of annual general meeting in SynAct Pharma AB